Controlling symptoms and maintaining mobility is currently the hallmark of managing patients with Parkinson's disease.

Management of Essential Tremor prioritizes functional improvement over symptom elimination, and protocols begin with propranolol or primidone.

(RTTNews) - Praxis Precision Medicines, Inc. (PRAX) on Monday said the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to ulixacaltamide for the treatment of patients ...

The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential tremor Praxis remains on track to submit ulixacaltamide NDA in ...

GOING TO BE VERY MILD. I’LL HAVE THAT FOR YOU COMING UP. ALL RIGHT. THANKS, MO. A GROUNDBREAKING TREATMENT FOR PARKINSON’S AND TREMORS IS NOW AVAILABLE IN KENTUCKY. THE NORTON NEUROSCIENCE INSTITUTE ...

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Praxis Precision Medicines Inc. (NASDAQ:PRAX) affirmed ...

Shares is Praxis Precision Medicines rose in premarket trading Friday after it said it expects to submit to U.S. regulators a new drug application next year for its investigational drug to treat ...

Praxis Precision Medicine said it had completed its pre-new drug application meeting with the Food and Drug Administration for its essential tremor treatment. The company said Thursday it expects to ...

A wearable, artificial intelligence (AI)-driven, continuous-use transcutaneous peripheral nerve stimulation (TPNS) device was linked to significant improvement in upper limb tremor in adult patients ...

Good day. Thank you for standing by. Welcome to the Praxis Precision Medicines Essential3 Topline Results Conference Call. [Operator Instructions] Please note that today's conference may be recorded.